How Analysts Feel About Atrion Corporation (NASDAQ:ATRI) After Increase in Sellers?

November 10, 2018 - By James Guidry

Investors sentiment increased to 1.4 in Q2 2018. Its up 0.10, from 1.3 in 2018Q1. It increased, as 8 investors sold Atrion Corporation shares while 35 reduced holdings. 21 funds opened positions while 39 raised stakes. 1.06 million shares or 1.48% less from 1.07 million shares in 2018Q1 were reported.
Bank Of Montreal Can reported 0% of its portfolio in Atrion Corporation (NASDAQ:ATRI). Legal And General Gru Public Ltd Llc owns 231 shares or 0% of their US portfolio. Strs Ohio invested in 0% or 1,400 shares. Proshare Limited Liability Co holds 0.05% of its portfolio in Atrion Corporation (NASDAQ:ATRI) for 11,376 shares. Schroder Management Group reported 1,033 shares. 2,645 are held by Jpmorgan Chase And Co. Parametric Assoc Ltd Limited Liability Company reported 2,307 shares or 0% of all its holdings. Spark Inv Limited Co owns 0.08% invested in Atrion Corporation (NASDAQ:ATRI) for 2,200 shares. Northern Tru Corp reported 0% stake. 83,183 are held by Vanguard. Ameritas Investment Partners holds 0% or 110 shares. Chevy Chase Trust Hldgs stated it has 500 shares. 4,700 are owned by Martingale Asset Lp. Roberts Glore And Inc Il holds 3,785 shares. Financial Corporation reported 5 shares.

The stock of Atrion Corporation (NASDAQ:ATRI) registered an increase of 10.37% in short interest. ATRI’s total short interest was 18,100 shares in November as published by FINRA. Its up 10.37% from 16,400 shares, reported previously. With 3,600 shares average volume, it will take short sellers 5 days to cover their ATRI’s short positions. The short interest to Atrion Corporation’s float is 1.28%.

The stock increased 0.42% or $3 during the last trading session, reaching $713. About 6,085 shares traded. Atrion Corporation (NASDAQ:ATRI) has declined 4.20% since November 10, 2017 and is downtrending. It has underperformed by 19.82% the S&P500.

Atrion Corporation develops, manufactures, and sells fluid delivery devices, and ophthalmic and cardiovascular products worldwide. The company has market cap of $1.32 billion. The companyÂ’s fluid delivery products include valves that promote infection control and needle safety, as well as for use in intubation, intravenous, catheter, and other applications in the fields of anesthesia and oncology. It has a 39.04 P/E ratio. The Company’s cardiovascular products comprise MPS2 myocardial protection system that delivers fluids and medications, and mixes drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products that are used in heart bypass surgery.

More news for Atrion Corporation (NASDAQ:ATRI) were recently published by: Nasdaq.com, which released: “Research Report Identifies Loxo Oncology, Atrion, Alexander’s, Broadridge Financial Solutions, International Flavors …” on October 19, 2018. Globenewswire.com‘s article titled: “Atrion Reports Third Quarter Results” and published on November 09, 2018 is yet another important article.

Atrion Corporation (NASDAQ:ATRI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.